Pfizer's intellectual property management team scored a small but significant victory this week after being granted a reissue patent that will afford the company 18 additional months of market exclusivity for its blockbuster painkiller Celebrex.
--- # [](https://www.innovation-asset.com/) - [Decipher®](https://www.innovation-asset.com/products-decipher) - [Services](https://www.innovation-asset.com/products/professional-services-0) - [Resources](https://www.innovation-asset.com/resources) - [Blog](https://www.innovation-asset.com/blog) - [About Us](https://www.innovation-asset.com/about) - [Contact Us](https://www.innovation-asset.com/contact) # Innovation Asset Blog # Pfizer secures Celebrex patent extension by [Peter Ackerman](https://www.innovation-asset.com/blog/author/peter-ackerman) Pfizer scored a small but significant victory this week after being granted a reissue patent that will afford the company 18 additional months of market exclusivity for its blockbuster painkiller Celebrex. "We are pleased with the reissuance of this patent protecting the invention of using \[the active ingredient\] celecoxib to treat osteoarthritis and other approved conditions, and have initiated legal proceedings to enforce our intellectual property rights through December 2, 2015," Pfizer general counsel Amy Shulman [stated](http://pfizer.newshq.businesswire.com/press-release/united-states-patent-trademark-office-grants-pfizer-reissue-patent-celebrex-celecoxib-). Those forthcoming enforcement efforts will be targeted at several generic drug manufacturers who had secured rights to sell their alternative products following Pfizer's former patent cliff of May 2014. According to [The Wall Street Journal](http://online.wsj.com/article/SB10001424127887323494504578342211494975622.html), this news has already created both upstream and downstream ripple effects. Investors were encouraged to hear about the extension of Celebrex's market monopoly, and Pfizer's shares rose nearly 2 percent immediately following the announcement. But according to the Journal, both distributors and customers were disheartened by the realization that they must continue to pay premium prices with no alternative available until the end of 2015.  ### [Peter Ackerman](https://www.innovation-asset.com/blog/author/peter-ackerman) Founder & CEO, Innovation Asset Group, Inc. [March 05, 2013](https://www.innovation-asset.com/blog/pfizer-secures-celebrex-patent-extension) ### Subscribe to Email Updates ### Introducing Decipher® ### Categories - [Intellectual Property Management (459)](https://www.innovation-asset.com/blog/topic/intellectual-property-management) - [Commercialization and Licensing (210)](https://www.innovation-asset.com/blog/topic/commercialization-and-licensing) - [Invention Disclosure (201)](https://www.innovation-asset.com/blog/topic/invention-disclosure) - [Innovation Strategy (20)](https://www.innovation-asset.com/blog/topic/innovation-strategy) - [Ideas for Good (6)](https://www.innovation-asset.com/blog/topic/ideas-for-good) - [Innovation Team (3)](https://www.innovation-asset.com/blog/topic/innovation-team) ### News Archives - [January 2013 (26)](https://www.innovation-asset.com/blog/archive/2013/01) - [September 2012 (25)](https://www.innovation-asset.com/blog/archive/2012/09) - [October 2012 (22)](https://www.innovation-asset.com/blog/archive/2012/10) - [November 2012 (22)](https://www.innovation-asset.com/blog/archive/2012/11) - [November 2010 (21)](https://www.innovation-asset.com/blog/archive/2010/11) - [February 2011 (21)](https://www.innovation-asset.com/blog/archive/2011/02) - [July 2012 (21)](https://www.innovation-asset.com/blog/archive/2012/07) - [December 2012 (21)](https://www.innovation-asset.com/blog/archive/2012/12) - [January 2012 (20)](https://www.innovation-asset.com/blog/archive/2012/01) - [March 2012 (20)](https://www.innovation-asset.com/blog/archive/2012/03) ##### Portland, Oregon USA ##### © Innovation Asset Group, Inc. ##### [Privacy Policy](https://www.innovation-asset.com/privacy-policy/) | [Terms & Conditions](https://www.innovation-asset.com/terms-and-conditions/) | [Contact Us](https://www.innovation-asset.com/contact/) -